# Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Study · id `cardio:ct-nct02582242` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02582242](<https://clinicaltrials.gov/study/NCT02582242>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02582242

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 437 participants.

## Technical summary

Registry record NCT02582242. Randomized; no masking; primary purpose treatment. Start 2015-10-19 (actual); primary completion 2017-03-18 (actual). Results posted on 2018-05-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 437 participants (enrolled count; ClinicalTrials.gov record NCT02582242, source copy `cardio:ctgov-nct02582242-2019-06-11`, retrieved 2026-10-26)
- Started: 2015-10-19 (actual) (ClinicalTrials.gov record NCT02582242, source copy `cardio:ctgov-nct02582242-2019-06-11`, retrieved 2026-10-26)
- Primary completion: 2017-03-18 (actual) (ClinicalTrials.gov record NCT02582242, source copy `cardio:ctgov-nct02582242-2019-06-11`, retrieved 2026-10-26)
- Completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT02582242, source copy `cardio:ctgov-nct02582242-2019-06-11`, retrieved 2026-10-26)
- Results first posted: 2018-05-29 (ClinicalTrials.gov record NCT02582242, source copy `cardio:ctgov-nct02582242-2019-06-11`, retrieved 2026-10-26)
- Countries: Algeria; China; Hong Kong SAR China; India; Taiwan; Türkiye; Ukraine (ClinicalTrials.gov record NCT02582242, source copy `cardio:ctgov-nct02582242-2019-06-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02582242-2019-06-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
- Condition: Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): biphasic insulin aspart 30
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs (`cardio:pubmed-30872064`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 76adbeab8c83bead78fdc47716afef1f5b70743a4e079cdca2a50ee0c3f2dde2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
